Medicus Pharma Files Streamlined Phase 2b/3 Protocol for Teverelix With FDA

Medicus Pharma (MDCX) submitted a streamlined Phase 2b/3 protocol to the FDA on September 29, 2026, for Teverelix in advanced prostate cancer patients at increased cardiovascular risk. The single-trial design could cut the company's planned clinical program by about 60%, reducing enrollment from roughly 1,500 to about 600 patients. The proposed trial would initially enroll about 80 patients, then add approximately 528 more if predefined criteria are met, for a total of about 608. It will evaluate testosterone suppression and cardiovascular effects, including a 12-month coronary plaque endpoint measured by coronary CT angiography. MDCX closed at $0.15 on September 28, down 0.20%. Shares were up 0.20% at $0.15 in pre-market trading.